Celgene Corporation (CELG)
(Delayed Data from NSDQ)
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.88 USD
+1.67 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $96.84 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
J&J's (JNJ) Darzalex Faspro Gets FDA Nod for Amyloidosis
by Zacks Equity Research
J&J (JNJ) gets accelerated approval for a new indication of Darzalex Faspro in combination with bortezomib, cyclophosphamide and dexamethasone for treating amyloidosis patients.
Fate Therapeutics Surges on Immunotherapy Deal With J&J
by Zacks Equity Research
Fate Therapeutics (FATE) signs agreement with J&J subsidiary to develop CAR NK and CAR T-cell product candidates for cancer. The deal is likely tocreate significant future revenue stream for the company.
Biotech ETFs Hit New Highs on Deal Activities
by Sweta Killa
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
Bristol-Myers' Melanoma Study Misses Goal, Closes Celgene Deal
by Zacks Equity Research
Bristol-Myers' (BMY) late-stage study evaluating the Opdivo-Yervoy combo fails to meet a co-primary endpoint of recurrence-free survival in melanoma patients. The company wraps up Celgene acquisition.
Biotech ETF (BBH) Hits New 52-Week High
by Sweta Killa
This biotech ETF hits a new 52-week high. Are more gains in store for this ETF?
Biotech Stock Roundup: MYOV & KRTX Surge, Pipeline Updates From VRTX, CELG & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
Top Ranked Growth Stocks to Buy for November 20th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, November 20th
Celgene's Revlimid-Rituximab Combo Gets Positive CHMP Opinion
by Zacks Equity Research
Celgene (CELG) gets a positive CHMP opinion, recommending the approval of Revlimid in combination with Rituxan for the treatment of adult patients with previously treated FL.
Bristol-Myers Gets FTC Clearance for Celgene Acquisition
by Zacks Equity Research
Bristol-Myers (BMY) obtains FTC permission for the Celgene acquisition and will divest Otezla to Amgen.
Top Ranked Growth Stocks to Buy for November 18th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, November 18th.
Top Ranked Growth Stocks to Buy for November 14th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, November 14th
Biotech Stock Roundup: SLDB Plunges, CELG Gets FDA Nod for Reblozyl & Other Updates
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates along with collaboration deals.
Editas (EDIT) Beats on Q3 Earnings, Amends Celgene Deal
by Zacks Equity Research
Editas' (EDIT) portfolio currently lacks an approved product. The focus of third-quarter earnings call was on its pipeline development.
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene
Top Ranked Growth Stocks to Buy for November 12th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, November 12th
4 Biotech Stocks That Could Keep Beating Wall Street
by Zacks Equity Research
The biotechnology industry has lagged the broader market so far this year, but these four stocks have done pretty well and should continue to do so.
Celgene (CELG) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Celgene & Acceleron Get FDA Nod for Rare Blood Disorder Drug
by Zacks Equity Research
Celgene (CELG) and partner Acceleron obtain FDA approval for Reblozyl for the treatment of anemia in adult patients with beta thalassemia.
Corcept (CORT) Earnings Beat in Q3, Korlym Boosts Sales
by Zacks Equity Research
Corcept (CORT) rides high on both earnings and revenue beat in the third quarter.
Prothena (PRTA) Reports Narrower-than-Expected Loss in Q3
by Zacks Equity Research
Prothena (PRTA) posts a narrower Q3 loss while sales surpass estimates.
Will Celgene (CELG) Gain on Rising Earnings Estimates?
by Zacks Equity Research
Celgene (CELG) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Celgene (CELG) Is Up 3.16% in One Week: What You Should Know
by Zacks Equity Research
Does Celgene (CELG) have what it takes to be a top stock pick for momentum investors? Let's find out.
Is Celgene (CELG) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (CELG) Outperforming Other Medical Stocks This Year?
CELG vs. TECH: Which Stock Is the Better Value Option?
by Zacks Equity Research
CELG vs. TECH: Which Stock Is the Better Value Option?
3 Reasons Why Celgene (CELG) Is a Great Growth Stock
by Zacks Equity Research
Celgene (CELG) possesses solid growth attributes, which could help it handily outperform the market.